Dicerna Pharmaceuticals, Inc.

Lexington, MA

UEI
UPKXGEA9AKT6
CAGE
621R8
Primary NAICS
541711 Research and Development in Biotechnology
SAM.gov registration
Active through

Company facts

Self-certified in SAM.gov
  • For Profit Organization
Entity structure
Corporate Entity (Not Tax Exempt)
SAM.gov registration date
Physical address
75 Hayden Ave, Lexington, MA 02421, USA
Website
novonordisk-us.com
Founded
1923
Employees
50K-100K
Industry
  1. Health Care
  2. Pharmaceuticals, Biotechnology & Life Sciences
  3. Pharmaceuticals
SIC code
28 Chemical & Allied Products
Profiles

Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .

Grant awards

Award Agency Obligated Awarded
Development of an ALDH2-targeting rnai therapeutic for alcohol use disorders U44AA027404 National Institute on Alcohol Abuse and Alcoholism (NIH) $8,000,000
Optimization of a clinical stage nanoparticle drug delivery platform R44CA186410 National Institutes of Health $1,998,609
Optimization of a clinical stage nanoparticle drug delivery platform R43CA186410 National Institutes of Health $184,129

Quick answers

Is Dicerna Pharmaceuticals, Inc. registered in SAM.gov?

Yes. Dicerna Pharmaceuticals, Inc.'s SAM.gov registration is active through August 31, 2027.

What is Dicerna Pharmaceuticals, Inc.'s most recent federal award?

Dicerna Pharmaceuticals, Inc.'s most recent federal grant award is Development of an ALDH2-targeting rnai therapeutic for alcohol use disorders (U44AA027404), from National Institute on Alcohol Abuse and Alcoholism (NIH), on September 20, 2018.

On GovTribe

See Dicerna Pharmaceuticals, Inc.'s full federal record

  • Federal grant awards
  • Funding analysis by agency, NAICS and set-aside
  • Similar vendors
Try for free Login